New York, May 27, 2026, 12:08 (EDT)
- Quantum X Labs was trading around $4.26, up roughly 2.7%, last seen on the Nasdaq.
- NeuroThera shared new info on the CliniQuantum license deal with Quantum X Labs’ full subsidiary.
- The company is still small and early-stage, with filings flagging a going-concern risk.
Quantum X Labs Inc. shares moved higher Wednesday. Investors responded to new details about a CliniQuantum transaction involving the company’s quantum technology portfolio. The Nasdaq-listed company also named a new scientific adviser.
The stock last traded at $4.26, up 11 cents on the day, after moving between $4.14 and $4.35. Just 27,676 shares changed hands, a reminder of how thinly traded this small-cap remains.
Quantum X Labs started trading as QXL on April 30, after switching its name from Viewbix Inc. and shifting focus to quantum computing, quantum error correction, simulation and sensing. The company still runs its legacy digital advertising business.
NeuroThera Labs said Wednesday it is giving an update to investors on its planned buyout of about 54.01% of CliniQuantum Ltd., an Israeli private company working on quantum simulation and quantum Monte Carlo tools for clinical trial data. Quantum Monte Carlo are statistical methods used to model tough problems.
Quantum X Labs got mentioned in the latest update. NeuroThera said CliniQuantum’s main asset is a license deal from March 2 with Quantum X Labs Ltd.—which is fully owned by the old Viewbix—giving it patents and know-how about quantum simulation and quantum Monte Carlo for clinical trials. NeuroThera also said CliniQuantum is still in the early stages and hasn’t brought in revenue yet.
CliniQuantum has to pay Quantum X Labs $180,000 under a non-interest credit agreement, with the money due between 13 and 24 months after the deal closes. The agreement includes tiered royalties of 4% to 6% from future net sales, along with 15% of certain sublicense revenues.
QXL holders now have a clearer look at where future economics might come from. But it’s still far from bringing in any revenue.
Quantum X Labs on Tuesday said it named Professor Oren Kurland from the Technion – Israel Institute of Technology to its newly created Scientific Advisory Board. The company said the board will offer scientific guidance and help validate the direction of its technology.
The company said Kurland holds an endowed chair at Technion and focuses on information retrieval, data science and AI. He’s published over 100 peer-reviewed papers, according to the release, and has won faculty research awards from Google, Yahoo and IBM.
The wider quantum group was mixed with Rigetti Computing down roughly 3.5% and D-Wave Quantum off 4.1%. IonQ ticked up a bit. The move in QXL looked more tied to the stock than any broad sector rally.
But risks are clear. In its latest quarterly filing, Quantum X Labs warned that falling revenue puts its status as a going concern in question, a term auditors use if a company might not stay in business. At March 31, cash and cash equivalents were $1.793 million. Bank loans and convertible debt totaled $2.305 million. Accumulated deficit: $46.652 million.
The CliniQuantum deal hasn’t closed yet. NeuroThera said the deal still needs to clear conditions like TSX Venture Exchange acceptance. The company cautioned there’s no guarantee the transaction will happen as planned, or happen at all.
